Three-drug combination highly effective in patients with hig

A three-drug combination that sent chronic lymphocytic leukemia (CLL) into deep remissions in a broad group of patients in a clinical trial is highly effective in patients with high-risk forms of the disease, a new, phase 2 clinical trial led by Dana-Farber Cancer Institute investigators indicates.

Related Keywords

Rhode Island , United States , American , Christine Ryan , Matthew Davids , Emily Henderson , American Society Of Hematology , Genentech , Lifespan Health System , Beth Israel Deaconess Medical Center , Dana Farber Cancer Institute , American Society , Discovery Industry Focus , Blood , One , Bone Marrow , Dancer , Children , Hronic , Chronic Lymphocytic Leukemia , Clinical Trial , Hospital , Leukemia , Research ,